I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| endothelial cell | 12 studies | 23% ± 7% | |
| CD8-positive, alpha-beta T cell | 8 studies | 24% ± 6% | |
| CD4-positive, alpha-beta T cell | 7 studies | 29% ± 10% | |
| epithelial cell | 6 studies | 28% ± 10% | |
| natural killer cell | 6 studies | 28% ± 8% | |
| myofibroblast cell | 5 studies | 18% ± 3% | |
| pericyte | 5 studies | 17% ± 3% | |
| regulatory T cell | 5 studies | 21% ± 4% | |
| astrocyte | 5 studies | 23% ± 7% | |
| T cell | 5 studies | 22% ± 4% | |
| B cell | 4 studies | 19% ± 5% | |
| hematopoietic precursor cell | 4 studies | 24% ± 4% | |
| connective tissue cell | 4 studies | 22% ± 6% | |
| neuron | 4 studies | 24% ± 7% | |
| smooth muscle cell | 4 studies | 18% ± 3% | |
| fibroblast | 4 studies | 21% ± 5% | |
| pro-B cell | 4 studies | 27% ± 3% | |
| GABAergic neuron | 4 studies | 35% ± 11% | |
| glutamatergic neuron | 4 studies | 43% ± 13% | |
| oligodendrocyte | 4 studies | 20% ± 4% | |
| plasmablast | 3 studies | 41% ± 13% | |
| lymphocyte | 3 studies | 18% ± 1% | |
| CD16-negative, CD56-bright natural killer cell, human | 3 studies | 18% ± 2% | |
| ciliated cell | 3 studies | 19% ± 3% | |
| dendritic cell | 3 studies | 28% ± 2% | |
| abnormal cell | 3 studies | 24% ± 6% | |
| basal cell | 3 studies | 24% ± 6% | |
| transit amplifying cell | 3 studies | 30% ± 5% | |
| macrophage | 3 studies | 19% ± 4% | |
| effector CD8-positive, alpha-beta T cell | 3 studies | 27% ± 6% |
